ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Brilinta found to reduce bleeding vs dual therapy pharmatimes
April 01, 2020AstraZeneca has announced that the Phase IV independent TWILIGHT trial, Brilinta (ticagrelor) monotherapy reduced bleeding complications with no increased risk of ischaemic events in patients with diabetes undergoing percutaneous coronary intervention.
Pharma Sources Insight January 2025
